Results 21 to 30 of about 67,411 (205)

Drug-Induced Liver Injury Caused by Capecitabine: A Case Report and a Literature Review

Case Reports in Oncology, 2023
Chemotherapy is widely used in cancer treatment, and the drug Capecitabine is often used in treatment of breast cancer and usually well-tolerated. Toxicity from Capecitabine typically involves hand-foot syndrome, fatigue, nausea, reduced appetite, and ...
Miriam Hussein, Anders Bonde Jensen
doaj   +1 more source

Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial.

The Lancet Oncology, 2022
BACKGROUND Patients with HER2-positive metastatic breast cancer have a high risk of developing brain metastases. Efficacious treatment options are scarce.
Ming Yan, Q. Ouyang, T. Sun, L. Niu, Jin Yang, Li Li, Yuhua Song, Chun-fang Hao, Zhanhong Chen, A. Orlandi, Naohiro Ishii, K. Takabe, G. Franceschini, F. Ricci, C. Verschraegen, Zhenzhen Liu, Mengwei Zhang, H. Lv, Liping Liu, Xiaohong Yang, H. Xiao, Zhichao Gao, Xiaorui Li, Fangyuan Dong, Xiuchun Chen, J. Qiao, Guifang Zhang   +26 more
semanticscholar   +1 more source

Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis.

Annals of Oncology, 2021
BACKGROUND In the primary analysis of HER2CLIMB trial, tucatinib added to trastuzumab and capecitabine significantly improved overall (OS) and progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 (HER2+) metastatic ...
G. Curigliano, V. Mueller, V. Borges, E. Hamilton, S. Hurvitz, S. Loi, R. Murthy, A. Okines, E. Paplomata, D. Cameron, L. Carey, K. Gelmon, G. Hortobagyi, I. Krop, S. Loibl, M. Pegram, D. Slamon, J. Ramos, W. Feng, E. Winer   +19 more
semanticscholar   +1 more source

CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients

BMC Immunology, 2020
Background Early detection of capecitabine-resistance could largely increase overall survival of colorectal cancer (CRC) patients. Previous studies suggested examination of immune cells in peripheral blood would help to predict efficacy of chemotherapy ...
Yu Lu, Yizhou Huang, Lei Huang, Yanjie Xu, Zien Wang, Han Li, Ting Zhang, Ming Zhong, Wei-qiang Gao, Yan Zhang   +9 more
doaj   +1 more source

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Journal of Clinical Oncology, 2020
PURPOSE NALA (ClinicalTrials.gov identifier: NCT01808573) is a randomized, active-controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), plus capecitabine (N+C) against lapatinib, a reversible dual TKI ...
C. Saura, Mafalda Oliveira, Yin-Hsun Feng, M. Dai, Shang-Wen Chen, S. Hurvitz, Sung-Bae Kim, B. Moy, S. Delaloge, W. Gradishar, N. Masuda, M. Pálácova, M. Trudeau, J. Mattson, Y. Yap, M. Hou, M. De Laurentiis, Yu-Min Yeh, Hong‐Tai Chang, T. Yau, H. Wildiers, B. Haley, D. Fagnani, Yen-Shen Lu, J. Crown, Johnson Lin, M. Takahashi, T. Takano, M. Yamaguchi, T. Fujii, B. Yao, J. Bebchuk, K. Keyvanjah, R. Bryce, A. Brufsky   +34 more
semanticscholar   +1 more source

Visfatin and Resveratrol Differentially Regulate the Expression of Thymidylate Synthase to Control the Sensitivity of Human Colorectal Cancer Cells to Capecitabine Cytotoxicity

Life, 2021
Colorectal cancer (CRC) is a highly lethal malignant cancer. Capecitabine, a 5-fluororacil (5-FU) derivate, is its first-line drug, but the resistance of CRC to capecitabine is still the most challenging factor for curing patients.
Kuen-Lin Wu, Ko-Chao Lee, Chia-Kuang Yen, Cheng-Nan Chen, Shun-Fu Chang, Wen-Shih Huang   +5 more
doaj   +1 more source

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Journal of Clinical Oncology, 2020
PURPOSE In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib.
N. Lin, V. Borges, C. Anders, R. Murthy, E. Paplomata, E. Hamilton, S. Hurvitz, S. Loi, A. Okines, V. Abramson, Philippe Bédard, Mafalda Oliveira, V. Mueller, A. Zelnak, M. DiGiovanna, T. Bachelot, A. J. Chien, R. O'Regan, A. Wardley, A. Conlin, D. Cameron, L. Carey, G. Curigliano, K. Gelmon, S. Loibl, J. Mayor, S. McGoldrick, Xuebei An, E. Winer   +28 more
semanticscholar   +1 more source

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer

JAMA Network Open, 2022
Key Points Question Does targeting programmed cell death 1 or programmed cell death ligand 1 enhance the clinical benefits of anti–vascular endothelial growth factor therapy in patients with refractory metastatic colorectal cancer (mCRC)?
N. Mettu, F. Ou, T. Zemla, T. Halfdanarson, H. Lenz, Rimini Breakstone, P. Boland, O. Crysler, C. Wu, A. Nixon, E. Bolch, D. Niedzwiecki, Alicia Elsing, H. Hurwitz, M. Fakih, T. Bekaii-Saab   +15 more
semanticscholar   +1 more source

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Nature Communications, 2023
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing ...
F. Lynce, C. Mainor, Renee N. Donahue, Xue Geng, Greg Jones, I. Schlam, Hongkun Wang, N. Toney, C. Jochems, Jeffrey Schlom, J. Zeck, C. Gallagher, R. Nanda, D. Graham, E. Stringer-Reasor, N. Denduluri, Julie Collins, Ami Chitalia, S. Tiwari, Raquel Nunes, R. Kaltman, Katia Khoury, M. Gatti-Mays, P. Tarantino, S. Tolaney, S. M. Swain, Paula Pohlmann, H. Parsons, Claudine Isaacs   +28 more
semanticscholar   +1 more source

Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases

Cancer Communications, 2018
Background Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related death. Sorafenib, a multitarget angiogenesis inhibitor, is an approved frontline treatment for advanced HCC in Western countries, although a complete response (
Giovanni Brandi, Michela Venturi, Stefania De Lorenzo, Francesca Garuti, Giorgio Frega, Andrea Palloni, Ingrid Garajovà, Francesca Abbati, Gioconda Saccoccio, Rita Golfieri, Maria Abbondanza Pantaleo, Maria Aurelia Barbera   +11 more
doaj   +1 more source